FDA
-
-
-
-
-
-
-
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
-
-
-
-
-
-
-
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
-
-
-
-
-
-
-
JUVÉDERM® Day Returns to U.S. on August 19
-
-
-
-
-
-
-
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
-
-
-
-
-
-
-
EU panel backs AbbVie's Rinvoq for vitiligo treatment
-
-
-
-
-
-
-
Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
-
-
-
-
-
-
-
FDA approves AbbVie's pivekimab sunirine-PVZY for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
-
332,796 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

